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Aims Treatment decisions in patients with scimitar syndrome (SS) are often challenging, especially in patients with iso-
lated SS who are often asymptomatic and who might be diagnosed accidentally. We queried a large multi-
institutional registry of SS patients to evaluate the natural history of this condition and to determine the efficacy of
surgical treatment in terms of survival and clinical status.
...................................................................................................................................................................................................
Methods
and results
We collected data on 485 SS patients from 51 institutions; 279 (57%) patients were treated surgically (STPs) and
206 (43%) were clinically monitored (CMPs). Median age at last follow-up was 11.6 years (interquartile range
4–22 years). Overall survival probability at 30 years of age was 88% [85–92% confidence intervals (CI)] and was
lower in patients with associated congenital heart disease (CHD) (P < 0.001) and pulmonary hypertension
(P < 0.001). Most patients were asymptomatic at last follow-up (279/451, 62%); STPs were more frequently asymp-
tomatic than CMPs (73% vs. 47%, P < 0.001), with fewer cardiac [odds ratio (OR) 0.42, 95% CI 0.22–0.82] and re-
spiratory symptoms (OR 0.08, 95% CI 0.02–0.28). Many STPs (63/254, 25%) had stenosis/occlusion of the scimitar
drainage, and this was associated with a younger age at surgery (OR 0.4, CI 0.21–0.78).
...................................................................................................................................................................................................
Conclusion Patients with SS have a high overall survival. Survival probability was lower in patients with associated CHDs and in
patients with pulmonary hypertension. Surgical treatment of SS is beneficial in reducing symptoms, however, given
the significant risk of post-operative scimitar drainage stenosis/occlusion, it should be tailored to a comprehensive
haemodynamic evaluation and to the patient’s age.
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Introduction
Scimitar syndrome (SS) is a rare congenital heart defect (CHD) char-
acterized by anomalous venous drainage of part or the entire right
lung to the inferior vena cava, variable right lung hypoplasia, and vari-
able systemic blood supply to part of the right lung.1–3 Symptoms vary
dramatically and are difficult to ascribe to the anomalous pulmonary
vein drainage, to the presence of associated cardiac anomalies or to a
combination of both.4–11 Most patients present with symptoms during
early infancy and need prompt surgical intervention.2,6,7 Treatment de-
cisions are often challenging in patients with isolated SS (i.e. without
associated CHDs) who are often incidentally diagnosed during adoles-
cence or adulthood and they usually remain asymptomatic or mildly
symptomatic for many years and are able to lead a normal life.1,2,8,9,12
To address this issue, and with the aim of improving patient care and
clinical practice, we used a large multi-institutional registry of patients
* Corresponding author. Tel: þ39 049 8212410, Fax: þ39 049 8212409, Email: vladimiro.vida@unipd.it
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with SS to analyse the natural history of the condition, and the efficacy
of surgical treatment in terms of survival and clinical status. To our
knowledge, this is the largest series of SS patients reported thus far.
Methods
The Clinical Investigation Committee of the University Hospital of Padua
approved the retrospective review of medical records in accordance
with the protection of patient confidentiality. Patients were not identified
and individual consent was not required (protocol no. 18946/2016). Fifty-
one institutions contributed to data collection, including 40 European and
11 extra-European institutions. The study was conducted on the behalf
of the Association for European Pediatric Cardiology (AEPC) and of the
European Congenital Heart Surgeons Association (ECHSA). We
included data from any patient with SS who was treated surgically (STPs)
or clinically monitored (CMPs). Patients with SS who underwent repair
of associated CHDs without correction of the anomalous pulmonary
venous connection (n = 20) were considered CMPs. We excluded pa-
tients with a functional single ventricle (n = 18) because their outcome
could be influenced by their specific physiology. Demographic, clinical,
morphological, and operative data were collected. Other associated
CHDs were divided arbitrarily into simple CHDs (including atrial septal
defects and/or patent ductus arteriosus) and complex CHDs (including
all other CHDs). We defined pulmonary arterial hypertension as a the
presence of a mean pulmonary artery pressure above 25 mmHg at rest
or 50% above systemic level, either by direct measurement in a catheter-
ization laboratory or by two-dimensional echocardiography estimation
using tricuspid regurgitation Doppler velocity.13,14 We arbitrarily divided
patients into three groups according to their age at diagnosis: (i) neo-
nates/infants (<_1 year), (ii) children (between 1 and 10 years), and (iii)
adolescents/adults (>10 years).
Outcomes
Primary outcomes were to evaluate the natural history of this condition
and to determine the efficacy of surgical treatment in terms of survival
and clinical status (defined as the presence and type of symptoms at the
last clinical evaluation).
Statistical analysis
Continuous variables are expressed as median, with interquartile range
(IQR) and categorical variables as percentages (absolute numbers).
Univariate comparisons for nominal variables were performed with the
v2 test or the omnibus F test for continuous variables. No post hoc analysis
was performed. The relationship between continuous and nominal vari-
ables was assessed with the Mann–Whitney test. For multi-variable ana-
lysis, we used linear regression and logistic regression for continuous and
dichotomic variables, respectively. Survival curves were calculated with
the Kaplan–Meier method, and difference in survival probability by the
log-rank test.
To determine the efficacy of surgical treatment, we compared the out-
come of STPs with that of CMPs. Associations among clinical variables
and outcome measures were based on a logistic regression model for
binary outcomes and expressed as odds ratios (OR) or using a Cox pro-
portional hazard model, and expressed as hazard ratios (HR) with a 95%
confidence interval (CI). In case of multiple regressors, fit in both models
was evaluated using the Akaike information criterion and selected the
model with the lower value. Cross-validation and bootstrap (5000 runs)
techniques were applied to assess the fitting accuracy of the models.
Somer’s concordance index Dxy (the closer to 1 in absolute value the
better) was obtained to evaluate goodness of fit and adjusted for opti-
mism. To evaluate the efficacy of surgery, we built a propensity score
model15 to adjust for selection bias of patients selected for surgery, both
considering the overall population and patients with isolated SS. The se-
lection model was based on all baseline clinical variables (gender, age at
diagnosis, cardiac symptoms at diagnosis, respiratory symptoms at diag-
nosis, heart position, dilated right ventricle at diagnosis, associated CHDs,
systemic arterial supply (SAS) to the right lung, pulmonary hypertension,
and right pulmonary hypoplasia) and implemented using a genetic algo-
rithm.16 Patients were matched according to the propensity score on a 1:
1 basis. Bias-adjusted ORs and HRs were obtained17 by adjusting for pro-
pensity score and clustering by matched pairs using a Huber–White esti-
mator.18 Statistical significance was set at P < 0.05 (two-sided). P-values
are reported with Benjamini & Yekutieli correction for multiplicity.19 For
the analysis we used R-software,20 the Matching,21 Harrell’s rms22 pack-
age, and the alluvial package by Bojanowski and Edwards.23
Results
Patient population
We collected data on 485 patients from 51 institutions (Figure 1).
Each centre provided the data of a median of six patients (IQR 2–11).
Median age at diagnosis was 0.48 years (IQR 0.1–5.2 years). Most
Figure 1 Flowchart of the study.
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patients were women (n = 305, 63%). Diagnosis of SS was established
by two-dimensional echocardiography. Additional investigations
were: cardiac catheterization (n = 276, 57%), chest computed tomog-
raphy scan (n = 146, 30%), cardiac MRI (n = 72, 15%), and lung scintig-
raphy (n = 74, 15%). The propensity score model built to limit the
selection bias, used in the next sections, performed satisfactorily in
classifying STPs vs. CMPs (Dxy 0.48, after considering optimism with
10 000 bootstrap replications).
Anatomy
The anomalous right pulmonary venous drainage involved the infer-
ior lobe in 136 patients (28%), the inferior and middle lobes in 54
(11%) and the entire right lung in 278 (57%). Less frequent drainage
patterns were present in the remaining 17 patients (4%). Three hun-
dred and forty-six patients (71%) presented with some degree of
right lung hypoplasia (Table 1). The severity of right lung hypoplasia
correlated with age at diagnosis (the younger the patient, the more
............................................................................................
....................................................................................................................................................................................................................
Table 1 Demographic, clinical/instrumental data and outcomes according to the age of patients at diagnosis
Age groups (at diagnosis)
Overall Neonates/infants
(0–1 year)
Children
(1–10 years)
Adolescents/adults
(10 years)
P-value corrected
for multiplicity
Number of patientsa 485 (100%) n = 282 (58%) n = 113 (23%) n = 90 (19%)
Gender, femalea 305 (63%) 166 (59%) 70 (63%) 69 (77%) 0.03
Heart position
Dextrocardiaa 240 (49%) 148 (52%) 61 (54%) 31 (34%) 0.05
Mesocardiaa 83 (17%) 48 (17%) 19 (17%) 16 (18%)
Levocardiaa 163 (33%) 86 (30%) 33 (29%) 43 (48%)
Isolated formsa 186 (38%) 81 (29%) 57 (50%) 48 (53%) 0.003
Associated CHDa 299 (62%) 199 (71%) 60 (53%) 40 (44%) 0.003
Simple CHDsa 198 (41%) 116 (41%) 49 (43%) 33 (37%)
Complex CHDsa 101 (21%) 83 (29%) 11 (9.7%) 7 (7.8%)
Atrial septal defect 243 (50%) 156 (55%) 56 (46%) 35 (39%) 0.01
Right pulmonary hypoplasiaa 346 (71%) 220 (78%) 76 (67%) 50 (55%) 0.003
Degree of RPH
Milda 204 (59%) 115 (52%) 50 (66%) 39 (78%) 0.003
Moderatea 96 (28%) 65 (30%) 21 (28%) 10 (20%)
Severea 46 (13%) 40 (18%) 5 (6%) 1 (2%)
Symptoms at diagnosisa 353 (73%) 220 (78%) 73 (65%) 60 (67%) 0.047
Cardiac symptomsa 227 (47%) 168 (60%) 29 (27%) 30 (33%) 0.006
Respiratory symptomsa 243 (50%) 140 (50%) 59 (52%) 44 (49%) 0.99
Dilated RV at diagnosis (at 2D-echo)a 332 (68%) 186 (66%) 84 (74%) 62 (69%) 0.99
Cardiac catheterizationa 276 (57%) 154 (55%) 75 (66%) 47 (52%) 0.24
Qp:Qsb 2.1:1 (1.5:1–2.6:1) 2:1 (1.4:1–2.7:1) 1.8:1 (1.5:1–2.3:1) 2:1 (1.6:1–2.2:1) 0.99
mPAP (mmHg)b 24 (18–34) 26 (20–40) 20.5 (17–30) 24 (18.5–28) 0.006
Pulmonary hypertensiona 157 (32%) 112 (40%) 28 (25%) 17 (19%) 0.006
SAS to the right lunga 248 (51%) 182 (65%) 49 (43%) 17 (19%) 0.006
Embolization of SASa 177 (71%) 132 (47%) 33 (29%) 12 (13%) 0.006
STPsa 279 (58%) 142 (51%) 78 (69%) 59 (66%) 0.03
CMPsa 206 (42%) 140 (49%) 35 (31%) 31 (34%) —
Time to last follow-up (years)b 7.2 (2.2–14) 6.4 (1.8–12.7) 9.9 (3.7–17) 7.5 (2.3–12) 0.02
Overall mortalitya 41 (8.7%) 37 (13%) 4 (3.5%) — 0.01
STPs hospital mortalitya 17 (6%) 14 (9.8%) 3 (3.8%) — 0.08
STPs late mortalitya 11 (3.9%) 10 (7%) 1 (1.3%) — 0.08
CMPs mortalitya 13 (6.3%) 13 (9.3%) — — 0.14
Symptoms at follow-upa 172/451 (37%) 109 (42%) 33 (31%) 30 (35%) 0.24
Cardiac symptomsa 227 (47%) 168 (60%) 29 (27%) 30 (33%) 0.01
Respiratory symptomsa 243 (50%) 140 (50%) 59 (52%) 44 (49%) 0.99
ASA, systemic arterial supply; CHD, congenital heart disease; CMPs, clinically monitored patients; Qp, Qs, pulmonary-systemic blood flow ratio; mPAP, mean pulmonary artery
pressure; RV, right ventricle, STPs, surgically treated patients; 2D, two-dimensional.
aNumber of patients and percentage.
bMedian and interquartile range.
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..severe the right lung hypoplasia, OR 0.88, 95% CI 0.81–0.96) and
with the presence of symptoms (OR 1.48, 95% CI 1.24–1.76). Other
associated CHDs were present in 299 patients (62%) (see
Supplementary material online, Table S1): simple CHDs in 198 (41%)
and complex CHDs in 101 (21%) patients. Atrial septal defect ostium
secundum type was the most common associated CHD (n = 243 pa-
tients, 50%). The remaining 186 patients (38%) had isolated SS (see
Supplementary material online, Table S2). An anomalous SAS to the
right lung was demonstrated in 248 patients (51%) and its occlusion
was deemed necessary in 177 patients (36%). A total of 332 patients
(68%) had moderate/severe dilatation of the right ventricle.
Clinical presentation
Most patients were diagnosed in the neonatal/infant period (n =
282, 58%), 113 (23%) during childhood, and 90 (19%) in adoles-
cence or adulthood. Three hundred and fifty-three patients (73%)
were symptomatic upon diagnosis: respiratory symptoms (includ-
ing respiratory distress, recurrent upper respiratory tract infec-
tions, cyanosis, and pneumonia) occurred in 243 patients (50%)
and cardiac symptoms (including failure to thrive and congestive
heart failure) in 227 patients (47%) (117 patients had mixed car-
diac and respiratory symptoms). The remaining 132 patients
(27%) were asymptomatic at diagnosis (65 patients having isolated
SS). Neonates/infants were more frequently symptomatic at diag-
nosis (P = 0.047) than patients in the other two age-groups, and
symptoms were mainly of cardiac origin (P = 0.02). At univariate
analysis, cardiac symptoms were correlated to the presence of
collateral arteries supplying the right lung (P = 0.03) and to right
ventricular dilatation (P = 0.01). All these variables were statistic-
ally significant also at multi-variable analysis.
Physiology
One hundred and fifty-seven patients (32%) had pulmonary arterial
hypertension, which was mostly seen in neonates/infants but was also
found in children and in adolescents/adults. This condition was more
frequent in patients with other associated CHDs (128/299 patients,
43%) than in patients with isolated SS (29/186 patients, 16%,
P = 0.01). The median pulmonary to systemic blood flow ratio
(Qp:Qs) was 2:1 (IQR 1.5:1–2.6:1). Univariate analysis revealed a cor-
relation between Qp:Qs and associated CHDs (P = 0.006), cardiac
symptoms (P = 0.02), and pulmonary hypertension (P = 0.01). At
multi-variable analysis only pulmonary hypertension was statistically
significant, which suggests a correlation among the explanatory
variables.
Early outcome of surgically treated
patients (hospital outcome)
Two hundred and seventy-nine patients (57%) were treated surgi-
cally (Figure 1). Median age at surgery was 4.2 years (IQR 0.5–
12.6 years); symptomatic patients were treated earlier (median age of
2.3 years, IQR 0.4–10.7 years) especially in case of cardiac symptoms
(median age of 0.8 years, IQR 0.3–6.7 years). Surgically treated pa-
tients more frequently had cardiac symptoms at diagnosis (147/279,
53%) than did CMPs (80/206, 39%, P = 0.003) (see Supplementary ma
terial online, Table S3). Two hundred and fifty-four patients (92%)
underwent correction of the anomalous venous drainage, and 25
(8%) underwent right lung resection, namely, right lung lobectomy (n
18) and right lung pneumectomy (n = 7). Patients who underwent
right pneumectomy/lobectomy were diagnosed earlier (median age
at diagnosis was 1 months, IQR 0.3–8 months vs. 12 months, IQR 1–90
months, P < 0.001), presented more frequently cardiac symptoms
....................................................................................................................................................................................................................
Table 2 Variables associated with mortality
Deaths Survivors
Hospital mortality (STPs) n 5 17 (6%) n 5 262 (94%) OR (95% CI)
Age at surgery (years)a 0.16 (0.08–0.3) 5 (0.7–15) 0.11 (0.01–0.79)
Associated CHDsb 16/17 (94%) 178/262 (68%) 2.23 (0.79–6.26)
Complex CHDsb 8/17 (47%) 55/262 (21%) 12.21 (1.48–100.42)
Pulmonary hypertensionb 12/17 (71%) 93/262 (36%) 2.33 (1.05–5.16)
Cardiac symptomsb 17/17 (100%) 130/262 (49%) 24.6 (3.31–183.6)
Follow-up mortality (STPs) n 5 11 (4.3%) n 5 243 (95.7%) HR (95% CI)
Age at surgery (years)a 0.2 (0.6–2.3) 14 (7–24) 0.07 (0.01–0.42)
Associated CHDsb 11/11 (100%) 161/243 (66%) 2.99 (1.40–6.40)
Complex CHDsb 7/11 (64%) 44/243 (18%) 25.51 (3.36–193.3)
Pulmonary hypertensionb 10/11 (91%) 83/243 (34%) 3.31 (1.72–6.38)
Cardiac symptomsb 10/11 (91%) 117/43 (48%) 17.8 (4.28–73.68)
Natural history mortality (CMPs) n 5 13 (6.6%) n 5 184 (93.4%) HR (95% CI)
Associated CHDsb 11/13 (85%) 86/184 (47%) 2.99 (0.87–10.23)
Complex CHDsb 7/13 (54%) 30/184 (16%) 11.23 (2.33–54.15)
Pulmonary hypertensionb 8/13 (62%) 42/184 (23%) 7.02 (2.11–23.35)
Cardiac symptomsb 12/13 (92%) 64/184 (35%) 2.61 (1.14–6.01)
OR, odds ratio; HR, hazard ratio; CI, confidence interval; CHDs, congenital heart diseases; STPs, surgically treated patients.
aMedian and interquartile range percentile.
bNumber of patients and percentage: n (%).
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(18/25, 72%, vs. 129/254, 51%, P = 0.05) and had more frequently a
moderate/severe degree of right lung hypoplasia (11/17, 64% vs. 68/
254, 39%, P = 0.01) then patients who underwent corrective surgery.
Corrective procedures were re-routing the scimitar vein into the
left atrium (n = 176 patients) and direct ‘scimitar vein re-implantation’
into the left atrium (n = 78 patients). Associated CHDs were repaired
during surgery. Ninety-three patients (33%) had postoperative com-
plications, which were more frequent in neonates/infants (65/142,
46%) than in children (18/78, 23%) or in adolescents/adults (10/19,
17%; P = 0.01). Seventeen patients (6%) died in hospital (Figure 1,
Table 1). Hospital mortality was lower for patients who underwent
corrective surgery than for patients who underwent right lung resec-
tion (8/254, 3.1% vs. 9/25, 36%, P = 0.01) (see Supplementary material
online, Table S4). Variables associated with hospital mortality are
listed in Table 2.
Follow-up outcomes
Follow-up data were available for 451/468 (96%) patients. Median
age at last clinical/instrumental evaluation was 11.6 years (IQR 4–22
years, maximum 78 years) and it was higher in STPs (14 years, IQR
6.5–24 years) than in CMPs (8 years, IQR 2.4–18 years; P < 0.001).
Twenty-four patients died during follow-up, 11/254 STPs (4.3%) all
after corrective surgery, and 13/197 CMPs (6.6%) (see
Supplementary material online, Table S4). Variables associated with
mortality are listed in Table 2. Overall survival probability at 30 years
of age was 88% (CI 85–92%) was lower in patients with associated
CHDs (P < 0.001) and in patients with pulmonary hypertension
(P < 0.001) (Figure 2). The presence of pulmonary hypertension was
associated with a lower survival, both in patients with isolated SS
than in patients with associated CHDs (Figure 2).
The majority patients were asymptomatic at the last clinical exam-
ination (279/451, 62%) (Figure 3) and symptoms were fewer in STPs
than in CMPs (OR 0.16, CI 0.08–0.32); this applies to both cardiac
(OR 0.42, CI 0.22–0.82) and respiratory symptoms (OR 0.12, CI
0.05–0.28). Also considering patients with isolated SS only (n = 186/
485), both cardiac (OR 0.20, CI 0.04–0.95) and respiratory symptoms
(OR 0.08, CI 0.02–0.28) were fewer at follow-up in STPs than in
CMPs.
Coil embolization of anomalous SAS to the right lung was associ-
ated with a reduction of cardiac symptoms between diagnosis and
the last clinical examination in CMPs (OR 3.72, CI 1.48–9.35).
Variables associated with last clinical status are listed in Table 3.
No patient who was asymptomatic at diagnosis developed symp-
toms after surgical treatment (0/65, 0%), whereas 6/60 (10%) of
asymptomatic CMPs developed symptoms at the last clinical examin-
ation (P = 0.01): cardiac symptoms in three patients and respiratory
symptoms in three others.
Late surgical complications in surgically
treated patients
Sixty-three patients (25%) had an instrumental diagnosis of stenosis/
occlusion of the scimitar drainage after a corrective procedure. This
diagnosis was unrelated to the type of corrective technique used and
it was more frequent in neonates/infants (n = 40/12, 33%) than in ei-
ther children (n = 15/75, 20%) or adolescents/adults (n = 8/57, 14%;
P = 0.01). There was an inverse linear correlation between age at
Figure 2 Survival probability according to Kaplan–Meier (age of
patients at last follow-up examination with 95% confidence bands)
of patients with pulmonary hypertension: (A) overall population and
stratified by (B) patients with isolated SS (without congenital heart
diseases, CHDs) and (C) patients with associated CHDs. SS, scimitar
syndrome.
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Figure 3 Flowchart showing the variation of patient’s clinical status between the diagnosis and last follow-up examination (stratified by natural
history vs. surgical treatment).
....................................................................................................................................................................................................................
Table 3 Variables associated with late clinical outcome (symptomatic vs. asymptomatic patients)
Symptomatic
points n 5 172 (38%)
Asymptomatic
points n 5 279 (62%)
STPs (n 5 254) n 5 68 (27%) n 5 186 (73%) HR (95% CI)
Associated CHDsa 54/68 (79%) 118/186 (63%) 1.45 (0.73–2.9)
Complex CHDsa 19/68 (28%) 32/186 (17%) 1.80 (1.07–3.02)
Pulmonary hypertensiona 35/68 (51%) 58/186 (31%) 2.02 (1.18–3.46)
Cardiac symptomsa 53/68 (78%) 74/186 (40%) 5.81 (3.14–10.77)
CMPs (n 5 197) n 5 104 (53%) n 5 93 (47%) HR (95% CI)
Pulmonary hypertensiona 38/104 (37%) 12/93 (13%) 5.16 (2.32–11.47)
Cardiac symptomsa 60/104 (58%) 16/93 (17%) 8.40 (4.06–17.36)
STPs, surgically treated patients; CMPs, clinically monitored patients; OR, odds ratio; HR, hazard ratio; CI, confidence interval; CHDs, congenital heart diseases.
aNumber of patients and percentage: n (%).
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..correction and stenosis/occlusion of the scimitar drainage (the
younger the patient, the higher incidence of stenosis/occlusion) (OR
0.4, CI 0.21–0.78). Forty-two of these 63 patients (67%) underwent
re-operation or haemodynamic intervention at a median of 0.8 years
(IQR 0.5–1.2 years) after repair. The outcome of patients with post-
operative scimitar vein stenosis/occlusion is shown in Figure 4.
Discussion
The clinical presentation of patients with SS is extremely variable.
Symptomatic patients with SS, especially in case of cardiac symptoms,
usually need prompt surgical intervention;2,24 this consists of redirec-
tion of the anomalous pulmonary venous drainage into the left
atrium.25–27 Right lung lobectomy or pneumonectomy may be
required in patients with severe clinical features.2,28,29 Treatment de-
cisions (i.e. to treat them surgically or to follow them medically) are
often challenging in patients with less severe forms1,2,8,9 who are
often asymptomatic and who might be diagnosed incidentally.
According to our data, the overall survival of patients with SS is
high, and the majority of our patients are asymptomatic at the late
clinical examination. Notably, the success of surgery was related to
the age of patients. Patients requiring surgical treatment under 1 year
of age are usually very ill, and have a relatively high-operative mortal-
ity and complication rate, whereas older patients have a better out-
come both immediately and in the long term. Surgically treated
patients had a significant higher proportion of simple CHD compared
with CMP (mainly ASD); this could be an explanation why there was
a higher left-to-right shunt and the reason why these patients were
diagnosed and operated earlier. We found that surgical treatment is
beneficial in reducing symptoms and it reduces the risk of developing
late symptoms. The therapeutic occlusion of any significant anomal-
ous SAS to the right lung30 significantly improved the clinical status of
patients with congestive heart failure, thus postponing the need for
surgical treatment.
Pulmonary hypertension and the presence of associated CHDs, in
particular complex CHDs, were negative prognostic factors in the
survival of patients, irrespective if patients were treated surgically or
followed in their natural history. Pulmonary hypertension was found
in more than one-third of our patients, and it was mostly seen in pa-
tients with associated CHDs, showing a correlation among these
variables. Nonetheless, even patients with isolated SS may present
with pulmonary hypertension.
Even considering the good results of surgery, we found that SS
corrective surgery is not complication-free, and almost 25% of our
STPs had scimitar vein-related morbidities (i.e. stenosis/occlusion of
the scimitar drainage), which in most cases (more frequently in neo-
nates/infants than in older patients) required additional surgical or
haemodynamic interventions. Given the not negligible associated
early and late morbidities in STPs, we suggest that surgical redirection
of the anomalous pulmonary venous drainage in patients with iso-
lated SS should be considered only when the scimitar drainage causes
considerable pulmonary overload (Qp:Qs > 1.5:1) (Figure 5). We be-
lieve that in selected patients, the correction of associated CHDs to-
gether with the therapeutic occlusion of SAS to the lung may be
beneficial, and so avoid or postpone the need for surgical correction
of SS to an older age (especially in asymptomatic patients), and so de-
crease the risk of late morbidities.
Based on this study, we suggest that patients with SS undergo con-
tinuous clinical and non-invasive monitoring (with MRI) to identify
clinical or physiological variations in order to administer timely ap-
propriate treatment and to check postoperative outcomes. Cardiac
catheterization can be avoided in patients without intra- or extra-
cardiac shunts; however, it is necessary when pulmonary hyperten-
sion is suspected.
Limitations
This is a retrospective multi-centre data collection study, and inter-
institutional and intra-institutional variability of treatment strategies
cannot be excluded. In addition, the presence and degree of right
lung hypoplasia and right ventricular dilation were both qualitative
evaluations being based on the physician’s experience, and may vary
between centres. Moreover, the median age at last follow-up control
Figure 4 Flowchart showing the outcome of patients with postoperative scimitar vein stenosis/occlusion. *Two patients required a right lung lob-
ectomy. Four patients refused any additional treatment, and three patients are currently clinically monitored.
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was higher in STPs than in CMPs, although we adjusted for age using
the propensity score model. Lastly we have no or limited information
on functional class, imaging parameters on right ventricular dilatation
and function, and arrhythmias.
Conclusions
We report the outcome of the largest series of SS patients hitherto
evaluated. We conclude that the overall survival of patients with SS is
high, and survival probability is lower in patients with associated
CHDs and in patients with pulmonary hypertension. Surgical treat-
ment of SS is beneficial in reducing symptoms. Surgical repair is indi-
cated in symptomatic patients and in patients with significantly
increased pulmonary blood flow. In asymptomatic patients, it must
be tailored to a comprehensive haemodynamic evaluation (i.e.
proved considerable pulmonary overload of the scimitar vein
drainage) and to the patient’s age because there is a high risk of de-
veloping postoperative scimitar drainage stenosis/occlusion.
We believe that in selected patients, correction of associated
CHDs together with the therapeutic occlusion of SAS to the lung
may be beneficial, and so avoid or postpone the need for surgical cor-
rection of SS to an older age, and so decrease the risk of late morbid-
ities. A continuous follow-up is indicated.
Figure 5 Flowchart showing our therapeutic management plan for patients with scimitar syndrome (SS). ASD II, atrial septal defect ostium secun-
dum type; CMTs, clinically monitored patients; PAH, pulmonary arterial hypertension; Qp:Qs, pulmonary-systemic blood flow ratio; PDA, patent
ductus arteriosus; SAS, systemic arterial supply; STPs, surgically treated patients; TOF, tetralogy of Fallot; VSD, ventricular septal defect. *High risk
for late stenosis/occlusion of the scimitar drainage in neonates/infants.
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